CSIMarket
 
Karyopharm Therapeutics Inc   (KPTI)
Other Ticker:  
 
 
Price: $1.5100 $0.17 12.687%
Day's High: $1.55 Week Perf: 2.03 %
Day's Low: $ 1.34 30 Day Perf: 11.03 %
Volume (M): 1,727 52 Wk High: $ 4.87
Volume (M$): $ 2,607 52 Wk Avg: $1.69
Open: $1.41 52 Wk Low: $0.62



 Market Capitalization (Millions $) 173
 Shares Outstanding (Millions) 114
 Employees 315
 Revenues (TTM) (Millions $) 146
 Net Income (TTM) (Millions $) -140
 Cash Flow (TTM) (Millions $) -28
 Capital Exp. (TTM) (Millions $) 0

Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc. is a biopharmaceutical company that is primarily focused on the development and commercialization of novel therapies for the treatment of cancer and other related diseases. The company's core technology platform is based on the identification and targeting of nuclear transport mechanisms, which are essential for the survival and growth of cancer cells.

The company was founded in 2008 and is headquartered in Newton, Massachusetts. It has operations in Europe and Asia, with strategic partners and collaborators spanning across North America, South America, Europe, Asia, and Africa.

Karyopharm's lead product candidate is XPOVIO (selinexor), which was approved by the US FDA in 2019 for the treatment of relapsed or refractory multiple myeloma. Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that targets the nuclear export protein XPO1 (exportin 1), causing a buildup of tumor suppressor proteins in the nucleus of cancer cells, leading to cell death.

Apart from XPOVIO, Karyopharm has a pipeline of drug candidates in various stages of development, targeting multiple cancer indications, including acute myeloid leukemia, liposarcoma, diffuse large B-cell lymphoma, and others. The company is also exploring the potential of its technology platform for the treatment of neurodegenerative diseases, inflammation, and viral infections.

Karyopharm has established collaborations with leading academic institutions, such as the National Cancer Institute, Dana-Farber Cancer Institute, and the Memorial Sloan Kettering Cancer Center, to support the preclinical and clinical development of its drug candidates. The company has also partnered with leading pharma companies, such as Biogen, Antengene, and Ono Pharmaceutical, to expand its market reach and accelerate the commercialization of its products.

In summary, Karyopharm Therapeutics Inc. is a biopharmaceutical company that is committed to developing and commercializing innovative therapies for cancer and other diseases, based on its nuclear transport technology platform. With a growing pipeline of drug candidates, a strong scientific and clinical team, and strategic collaborations with leading institutions and pharma companies, Karyopharm is well-positioned to realize its vision of transforming cancer care and improving patient outcomes.


   Company Address: 85 Wells Avenue, 2nd Floor Newton 2459 MA
   Company Phone Number: 658-0600   Stock Exchange / Ticker: NASDAQ KPTI
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc makes significant strides in financial performance during Q3 2023

The stock market has always been a wild ride filled with ups and downs, but amidst the unpredictability, there are often glimmers of hope and opportunity. One such hopeful glimpse comes from Karyopharm Therapeutics Inc, a company that has seen some positive changes in its financials during the third quarter of 2023.
While it is true that the company experienced a loss, it is important to note that the loss per share has actually decreased when compared to the previous year. This shows that Karyopharm Therapeutics Inc is making progress and moving in the right direction. Additionally, the sequential decrease in revenue is minimal and does not raise any significant concerns.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc Reveals Impressive Leap in Earnings Despite Revenue Decline in Q2 2023



Karyopharm Therapeutics Inc, a leading pharmaceutical company, has witnessed a notable increase in its stock performance and financial results. With a 10.43% gain in stock value over the past week, along with a significant decrease in losses per share and improved earnings, the company seems to be on the right track. This article will analyze the impact of these positive developments on Karyopharm Therapeutics Inc's future prospects.
Positive Financial Results:
1. Improved Earnings per Share (EPS):
During the April to June 30, 2023 fiscal period, Karyopharm Therapeutics Inc managed to decrease its loss per share (EPS) from $-0.62 to $-0.29 compared to the same period last year. This significant improvement is expected to boost investor confidence and strengthen the company's financial standing.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc Shows Significant Improvement in First Quarter 2023 Earnings as Losses Shrink and Revenue Declines

Karyopharm Therapeutics Inc (KPTI) is a biopharmaceutical company that focuses on the development and commercialization of innovative cancer treatments. Headquartered in Massachusetts, United States, the company is led by an experienced team of scientists and industry veterans who have a proven track record of bringing breakthrough therapies to market.
The first quarter of the 2023 earnings season saw KPTI manage to reduce its losses on vanishing revenue. The company was successful in lowering its shortfall per share to $-0.30 compared to $-0.53 in the same financial reporting period a year ago. However, revenue also decreased by 18.821% to $38.70 million in proportion to $47.67 million reported a year ago.






 

Karyopharm Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com